Abstract 101P
Background
Immunotherapy has become a standard of care for recurrent and metastatic cervical carcinoma resulting in the need to carefully assess for surrogacy focusing on new therapeutic scenarios. This study delves into a systematic review and meta-analysis to unravel the potential of progression-free survival (PFS) as a surrogate endpoint in cervical cancer.
Methods
We performed a comprehensive search of randomized phase 2 and 3 clinical trials in advanced and recurrent cervical cancer. PRISMA guidelines were followed, and the study was registered in PROSPERO (CRD42023405604). Inclusion criteria required RCTs with mature PFS and OS data. Trials with adjuvant treatment or disease-free survival as primary endpoint were excluded. Subgroup analysis was performed by type of treatment (i.e. chemotherapy-based, chemo-immunotherapy combinations).
Results
11,348 articles were screened, and 31 included in the final analysis. In the overall population, a robust correlation between PFS and OS was observed (Spearman's rho = 0.66, p-value < 0.001). We calculated the Surrogate Threshold Effect (STE) at the PFS intersection with null OS outcome (p = 0.05), resulting in a threshold for PFS z-score (z-PFS) of 2.23. When examining the results by treatment modality, chemotherapy trials exhibited a notably weak and non-significant correlation (Spearman 0.34, p = 0.31) with a significantly higher STE (z-PFS = 2.92). Conversely, in chemo-immunotherapy combinations, the correlation was notably robust and statistically significant (Spearman 0.94, p = 0.017), associated with a considerably lower STE (z-PFS = 2.1).
Conclusions
PFS may serve as a surrogate endpoint in cervical cancer. Notably, PFS was a more promising surrogate marker in the context of chemo-immunotherapy when compared to chemotherapy alone. This aligns with the hypothesis that chemo-immunotherapy induces a response, which is further sustained through maintenance immunotherapy, thereby enabling PFS to better capture the impact on OS. Conversely, in chemotherapy-based treatments, the expected survival benefit may be more limited, and PFS may not as strongly capture the effect of chemotherapy alone.
Legal entity responsible for the study
European Organisation for Research and Treatment of Cancer (EORTC), Young Gynaecological Cancer Group.
Funding
Has not received any funding.
Disclosure
F. Herrera: Financial Interests, Institutional, Research Grant, Grant/Research Support: Accuracy Inc, Bioprotext, BMS, Roche-ImFlame/ImCore, Nanobiotix, AstraZeneca, Eisai, MSD, Seagen; Financial Interests, Institutional, Research Grant, Grant/Research Support Foundations: Prostate Cancer Foundation, San Salvatore Foundation; Financial Interests, Personal, Advisory Board, Consultation, fees, travel expenses: Johnson & Johnson, Seagen, MSD, BMS, AstraZeneca, Eisai; Non-Financial Interests, Institutional, Non-financial benefits, Academic Collaborations: EORTC chairman GCG, ESMO Scientific Committee member for drug development, ASTRO Scientific Committee Annual Meeting. A. Madariaga Urrutia: Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, Clovis, MSD; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display